Facebook
Twitter
LinkedIn
ForwardDebate on Advanced, Resectable cSCC in the Era of Immunotherapy: Cut Now, Later, or Not at All?
Advanced cutaneous SCC is becoming more prevalent, with more aggressive disease noted. There are now many different acceptable approaches to treating this disease, involving multidisciplinary expertise, including that of Dermatology (including Mohs surgeons), Surgeons (head and neck, plastics and reconstruction), radiation oncologists, and medical oncologists. This session will serve to present the most current and up to date evidence for treatment as well as provide real-world perspectives from leaders in field from a variety of disciplines.
Learning Objectives
Upon completion of this activity, participants should be able to do the following:
- Recognize clinical scenarios constituting advanced cSCC.
- Identify patients who would benefit from multidisciplinary approach to treatment planning.
- Become more aware of current accepted practice patterns.
Jessica Geiger, MD, is employed by the Cleveland Clinic and has no financial relationships with a commercial interest.
Shlomo Koyfman, MD, is employed by the Cleveland Clinic Foundation and receives research funding from BMS, Castle Biosciences, Merck and Regeneron. He serves on the advisory boards of BMS, Galera Therapeutics, Merck and Regeneron. He is also a consultant for Castle Biosciences. He receives additional compensation from UptoDate.
Emily Ruiz, MD, MPH, FAAD, is employed by Dana Farber/Brigham and Women's Cancer Center. She receives research funding from Castle Biosciences and Regeneron. She is also a consultant with Checkpoint Therapeutics and Regeneron. She serves in a leadership position with the American College of Mohs Surgery.
Steven Chinn, MD, MPH, is employed by the University of Michigan and has no financial relationships with a commercial interest.
All relevant relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
Available Credit
- 1.25 AMA PRA Category 1 Credit™The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.25 Certificate of AttendanceThis activity was designated for 1.25 AMA PRA Category 1 Credit™.